Influenza – Production of a live attenuated influenza virus vaccine

With a novel method it is possible for the first time to produce a live attenuated influenza A virus vaccine. The method is based on the production of specific mutants of influenza viruses which in vivo are in fact immunogenic, but not pathogenic. Their genome largely corresponds with that of the currently active epidemic strain, allowing their utilisation as attenuated recombinant vaccine against the influenza virus. Due to the particular characteristics of the influenza virus mutants, the application of this vaccine will be possible for children, elderly people and even immunodeficient people.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Perovskite solar cells soar to new heights

Metal halide perovskites have been under intense investigation over the last decade, due to the remarkable rise in their performance in optoelectronic devices such as solar cells or light-emitting diodes….

Blue hydrogen can help protect the climate

An international group of researchers led by the Paul Scherrer Institute and the Heriot-Watt University has carried out in-depth analyses of the climate impact of blue hydrogen. This is produced…

Genes associated with hearing loss visualised in new study

Researchers from Uppsala University have been able to document and visualise hearing loss-associated genes in the human inner ear, in a unique collaboration study between otosurgeons and geneticists. The findings…

Partners & Sponsors